[
    {
        "@context": "https://schema.org",
        "@type": "Report",
        "ticker": "3895",
        "company_name": "ハビックス株式会社",
        "title": "3895 ハビックス｜低PBR与ユニ・チャームOEM转型验证｜Kabugami研究报告",
        "url": "https://www.kabugami.jp/reports/3895/",
        "score": "70.5",
        "rating": "B+",
        "action": "观察仓 / 验证仓",
        "research_confidence": "中等",
        "published_date": "",
        "updated_date": "2026-08-02",
        "data_cutoff": "财务2026-03-31",
        "report_version": "V2.2",
        "pdf_url": "",
        "cover_url": "https://www.kabugami.jp/wp-content/uploads/2026/08/3895-cover.png",
        "excerpt": "",
        "updates_url": "https://www.kabugami.jp/reports/3895/updates.json",
        "llms_txt": "https://www.kabugami.jp/llms.txt",
        "license_note": "Kabugami.jp research; cite the canonical report URL and visible sources."
    },
    {
        "@context": "https://schema.org",
        "@type": "Report",
        "ticker": "4564",
        "company_name": "オンコセラピー・サイエンス株式会社",
        "title": "4564 オンコセラピー・サイエンス｜Kabugami标准化持续更新研究报告",
        "url": "https://www.kabugami.jp/reports/4564/",
        "score": "40",
        "rating": "C",
        "action": "重点观察",
        "research_confidence": "中等",
        "published_date": "2026-06-25",
        "updated_date": "2026-08-02",
        "data_cutoff": "财务2026-03-31｜股本及融资2026-06-30｜公开资料2026-08-02",
        "report_version": "V2.1",
        "pdf_url": "",
        "cover_url": "https://www.kabugami.jp/wp-content/uploads/2026/08/cover-1.png",
        "excerpt": "4564拥有真实的癌症基因组解析业务和多项科学资产，但长期亏损、外部合作依赖与持续股本扩张削弱普通股东价值。当前评分40／100，C评级，定位为重点观察。",
        "updates_url": "https://www.kabugami.jp/reports/4564/updates.json",
        "llms_txt": "https://www.kabugami.jp/llms.txt",
        "license_note": "Kabugami.jp research; cite the canonical report URL and visible sources."
    }
]